<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511771</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919A2433</org_study_id>
    <nct_id>NCT00511771</nct_id>
  </id_info>
  <brief_title>A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</brief_title>
  <official_title>A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To provide tegaserod to eligible women adult patients who did not have satisfactory
      improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic
      constipation (CIC) symptoms with other available treatment(s) and / or patients who had
      satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Irritable Bowel Syndrome With Constipation</condition>
  <condition>Chronic Idiopathic Constipation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod</intervention_name>
    <description>Tegaserod maleate</description>
    <other_name>Zelnorm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For patients with IBS-C: Women of 18-54 years of age with IBS-C according to the Rome
             III criteria.

          2. For patients with Chronic Idiopathic Constipation: Women of 18-54 years of age with
             CIC according to the Rome III criteria .

          3. Patients who did not have satisfactory symptom improvement of their IBS-C or CIC
             symptoms with other available treatment(s) and / or patients who had satisfactory
             improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.
             Satisfactory symptom improvement will be assessed by the patient.

          4. Patients signed the informed consent

        Exclusion Criteria:

          1. History of or current diagnosis of cardiovascular ischemic disease (e.g., angina
             pectoris, myocardial infarction, transient ischemic attack or stroke and including
             findings suggestive of ischemia on an ECG such as changes in ST segment and T waves,
             and / or Q wave)

          2. Patients who have uninvestigated symptoms suggestive of a cardiovascular ischaemic
             disease such as chest pain or chest discomfort, shortness of breath, sudden onset of
             weakness of the arms or the legs, difficult talking or loss of sensation etc

          3. Presence of any cardiovascular risk factors according to the NIH guideline [NIH
             Publication No. 01-3670] (such as hypertension, hyperlipidemia, diabetes mellitus,
             active smoking, obesity and family history of premature coronary heart disease) as
             assessed by the investigator

          4. Clinical evidence of significant (as judged by the Investigator) respiratory,
             cardiovascular, renal, hepatic-biliary, endocrine, psychiatric or neurologic diseases
             or presence of abdominal adhesions

          5. History of or current eating disorder such as anorexia or bulimia or compulsory
             overeating.

          6. Uncompensated depression or anxiety or suicidal ideation or behavior.

          7. Diagnosis of mega-rectum or colon, a history of intestinal obstruction, congenital
             anorectal malformation, clinically significant rectocele, or any evidence of
             intestinal structural abnormality including gastrointestinal resection that affected
             bowel transit or any evidence of intestinal carcinoma, of inflammatory bowel disease
             or of alarm symptoms such as weight loss, rectal bleeding, or anemia

          8. Evidence of cathartic colon or a history of drug (including laxative) or alcohol
             abuse, that in the Investigator's opinion, the patient is likely to continue to abuse
             these substances during the tIND program period

          9. Pregnant women or breastfeeding women; fertile women who are not currently practicing
             medically approved method of contraception

         10. Participating in other investigational studies concurrently or within 1 month prior to
             entering this tIND program

         11. Hypersensitive to tegaserod or to any of the excipients

         12. Patients who had tolerability or safety concerns with prior use of tegaserod.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
  </eligibility>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>November 16, 2010</last_update_submitted>
  <last_update_submitted_qc>November 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Tegaserod, treatment IND, irritable bowel syndrome with constipation, IBS-C, chronic idiopathic constipation, CIC, chronic constipation, CC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

